25 авг. 2021 г. · The round was led by Inkef Capital, supported by fellow new investors Fund+, Sunstone,. Hadean Ventures and Coparion with participation from ...

25 мар. 2024 г. · Novo Nordisk has agreed to acquire its portfolio company Cardior Pharmaceuticals for up to 1.025 billion Euros, including an upfront payment and additional ...

25 мар. 2024 г. · Novo Nordisk will acquire Cardior Pharmaceuticals for up to 1.025 billion euros, including upfront and additional payments if certain ...

Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics.

Cardior Pharmaceuticals was acquired by Novo Nordisk for $1.1B on Mar 25, 2024 .

Cardior Pharmaceuticals, non-coding rna-based therapeutics in heart failure. Here you'll find information about their funding, investors and team.

25 мар. 2024 г. · Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros.

Ascenion, BioMedPartners, Boehringer Ingelheim Venture Fund, Bristol-Myers Squibb, and Coparion are 5 of 14 investors who have invested in Cardior.

25 мар. 2024 г. · Novo Nordisk has agreed to acquire Cardior Pharmaceuticals for up to 1.025 billion Euros, including an upfront payment and additional payments.

Therapies for heart failure and related Cardiovascular Diseases. Sector: Healthcare. Country: Germany. Fund: LSP 5 Entry 2017. Axtarish: cardior.de